Loading...
Loading...
AFMD| Name | Value |
|---|---|
| Revenues | 11.2M |
| Cost of Revenue | 0.0M |
| Gross Profit | 11.2M |
| Operating Expense | 42.1M |
| Operating I/L | -30.1M |
| Other Income/Expense | -3.3M |
| Interest Income | -0.0M |
| Pretax | -33.4M |
| Income Tax Expense | 3.3M |
| Net Income/Loss | -36.7M |
Affimed N.V. is a clinical-stage biopharmaceutical company specializing in cancer immunotherapies. Its lead product candidate, AFM13, has completed Phase II clinical study for peripheral T-cell lymphoma and is in trials for other lymphomas. The company is also developing AFM24 and AFM28 for advanced cancers and acute myeloid leukemia, respectively. Additionally, AFM32 is in preclinical development for solid tumors. Affimed N.V. has collaboration agreements with leading institutions and research funding agreements. Its revenue is generated through the development and potential commercialization of its cancer immunotherapy products.
